when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Bizengri · news · pharmadog

← back to Bizengri

News mentioning Bizengri

21 stories

May 11, 26Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialbiopharma dive

May 11, 26Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTonclive

May 11, 26Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selectiononclive

May 11, 26Expanding ctDNA Applications to RCC and Germ Cell Tumorsonclive

May 11, 26RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practiceonclive

May 11, 26ctDNA in Metastatic Urothelial Carcinomaonclive

May 11, 26Institutional Perspectives on Treatment Thresholds in PLGGonclive

May 11, 26Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groupsonclive

May 10, 26Five Under 5: Top Oncology Videos for the Week of 5/3onclive

May 9, 26The OncFive: Top Oncology Articles for the Week of 5/3onclive

May 8, 26Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCTonclive

May 8, 26Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive

May 8, 26Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanomaonclive

May 8, 26Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhDonclive

May 8, 26Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Canceronclive

May 8, 26FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinomaonclive

May 5, 26Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congressonclive

May 5, 26The Type of Fat—Not the Amount—Fuels Pancreatic Canceronclive

May 5, 26Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCConclive

May 5, 26Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosisonclive

May 5, 26Coordinating Care in Multiple Myeloma Across Practice Settingsonclive